Last 12 months
Inside the activity.
0 purchase rows · 214 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 14 |
| Dec 2025 | 0 | 10 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 26 |
| Apr 2026 | 0 | 14 |
| May 2026 | 0 | 28 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 36 |
| Aug 2026 | 0 | 44 |
| Sep 2026 | 0 | 15 |
| Oct 2026 | 0 | 6 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 20, 2020 Filed Oct 22, 2020 20:06 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 100 | $50.09 | $5,009.00 |
DisclosureSEC source: 0001447362-20-000245 · wf-form4_160339714746734.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,414,348 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 20:06 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 900 | $49.61 | $44,645.40 |
DisclosureSEC source: 0001447362-20-000245 · wf-form4_160339714746734.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,414,448 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $49.060 to $50.030, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 20:03 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,500 | $50.16 | $75,240.00 |
DisclosureSEC source: 0001447362-20-000243 · wf-form4_160339697345220.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 791,828 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $50.05 to $50.35, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| October 20, 2020 Filed Oct 22, 2020 20:03 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 10,250 | $49.63 | $508,707.50 |
DisclosureSEC source: 0001447362-20-000243 · wf-form4_160339697345220.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 793,328 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $49.05 to $50.03, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| October 14, 2020 Filed Oct 14, 2020 23:11 UTC |
Cook Joseph C. IIIDirector
|
SaleCommon Stock | 700 | $55.14 | $38,598.00 |
DisclosureSEC source: 0001447362-20-000239 · wf-form4_160271705881736.xml · nonDerivative · entry 5 Cook Joseph C. III · CIK 0001783205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,178 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. Read SEC document |
| October 14, 2020 Filed Oct 14, 2020 23:11 UTC |
Cook Joseph C. IIIDirector
|
SaleCommon Stock | 5,775 | $54.51 | $314,777.93 |
DisclosureSEC source: 0001447362-20-000239 · wf-form4_160271705881736.xml · nonDerivative · entry 4 Cook Joseph C. III · CIK 0001783205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,878 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $54.140 to $55.135, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 20:20 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · derivative · entry 8 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,137 Underlying: Common Stock · 13,000 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F6 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 20:20 UTC |
Stokes FrankChief Financial Officer
|
SaleCommon Stock | 1,300 | $55.13 | $71,674.20 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 6 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,886 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $55.115 to $55.140, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 20:20 UTC |
Stokes FrankChief Financial Officer
|
SaleCommon Stock | 8,300 | $54.58 | $453,014.00 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 5 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,186 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $54.105 to $55.100, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 20:20 UTC |
Stokes FrankChief Financial Officer
|
SaleCommon Stock | 3,400 | $53.06 | $180,417.60 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 4 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,486 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $52.810 to $53.780, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 20:20 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionCommon Stock | 13,000 | $2.39 | $31,070.00 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 3 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 23:11 UTC |
Cook Joseph C. IIIDirector
|
SaleCommon Stock | 2,100 | $55.11 | $115,726.80 |
DisclosureSEC source: 0001447362-20-000239 · wf-form4_160271705881736.xml · nonDerivative · entry 3 Cook Joseph C. III · CIK 0001783205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,653 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $55.050 to $55.200, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 23:11 UTC |
Cook Joseph C. IIIDirector
|
SaleCommon Stock | 21,749 | $54.71 | $1,189,931.29 |
DisclosureSEC source: 0001447362-20-000239 · wf-form4_160271705881736.xml · nonDerivative · entry 2 Cook Joseph C. III · CIK 0001783205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,753 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $54.050 to $55.045, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:20 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · derivative · entry 7 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,137 Underlying: Common Stock · 13,000 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F6 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:20 UTC |
Stokes FrankChief Financial Officer
|
SaleCommon Stock | 13,000 | $54.79 | $712,283.00 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,886 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $54.280 to $55.200, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:20 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionCommon Stock | 13,000 | $2.39 | $31,070.00 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| October 12, 2020 Filed Oct 14, 2020 23:11 UTC |
Cook Joseph C. IIIDirector
|
SaleCommon Stock | 19,676 | $54.84 | $1,079,051.52 |
DisclosureSEC source: 0001447362-20-000239 · wf-form4_160271705881736.xml · nonDerivative · entry 1 Cook Joseph C. III · CIK 0001783205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,502 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $54.410 to $55.310, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 13:33 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 25,000 | $54.16 | $1,354,075.00 |
DisclosureSEC source: 0001447362-20-000235 · wf-form4_160259596962150.xml · nonDerivative · entry 2 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 883,577 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on May 22, 2020. F2 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 13:35 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 601 | $54.94 | $33,020.74 |
DisclosureSEC source: 0001447362-20-000237 · wf-form4_160259613860892.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 803,578 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $54.940 to $54.950, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| October 09, 2020 Filed Oct 13, 2020 13:35 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 14,399 | $54.60 | $786,156.60 |
DisclosureSEC source: 0001447362-20-000237 · wf-form4_160259613860892.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 804,179 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $53.940 to $54.930, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 13:33 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 25,000 | $54.23 | $1,355,777.50 |
DisclosureSEC source: 0001447362-20-000235 · wf-form4_160259596962150.xml · nonDerivative · entry 1 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 908,577 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on May 22, 2020. F2 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 13:35 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 700 | $54.53 | $38,167.50 |
DisclosureSEC source: 0001447362-20-000237 · wf-form4_160259613860892.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 818,578 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $54.480 to $54.550, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 13:35 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 14,300 | $53.89 | $770,655.60 |
DisclosureSEC source: 0001447362-20-000237 · wf-form4_160259613860892.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 819,278 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $53.465 to $54.445, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 20:16 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 50,000 | $53.09 | $2,654,655.00 |
DisclosureSEC source: 0001447362-20-000233 · wf-form4_160218819191283.xml · nonDerivative · entry 1 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 933,577 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on May 22, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $53.0300 to $53.1561, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 20:09 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 25,000 | $52.09 | $1,302,250.00 |
DisclosureSEC source: 0001447362-20-000231 · wf-form4_160201498604990.xml · nonDerivative · entry 2 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 983,577 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on May 22, 2020. F2 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| October 02, 2020 Filed Oct 5, 2020 20:07 UTC |
Aspinall Mara G.Director
|
SaleCommon Stock | 2,500 | $52.48 | $131,200.00 |
DisclosureSEC source: 0001447362-20-000229 · wf-form4_160192840876661.xml · nonDerivative · entry 1 Aspinall Mara G. · CIK 0001623049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,848 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 1, 2020. Read SEC document |
| October 02, 2020 Filed Oct 5, 2020 20:05 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 200 | $52.22 | $10,443.40 |
DisclosureSEC source: 0001447362-20-000228 · wf-form4_160192830937248.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,415,348 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $52.210 to $52.310, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 02, 2020 Filed Oct 5, 2020 20:05 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 5,800 | $51.64 | $299,517.80 |
DisclosureSEC source: 0001447362-20-000228 · wf-form4_160192830937248.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,415,548 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $51.140 to $52.125, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 02, 2020 Filed Oct 6, 2020 20:09 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 25,000 | $52.07 | $1,301,682.50 |
DisclosureSEC source: 0001447362-20-000231 · wf-form4_160201498604990.xml · nonDerivative · entry 1 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 1,008,577 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on May 22, 2020. F2 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 2,000 | $51.68 | $103,360.00 |
DisclosureSEC source: 0001447362-20-000228 · wf-form4_160192830937248.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,421,348 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $51.270 to $52.050, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 646 | $52.07 | $33,633.99 |
DisclosureSEC source: 0001447362-20-000228 · wf-form4_160192830937248.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,423,348 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $51.970 to $52.130, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:05 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 9,994 | $51.59 | $515,550.48 |
DisclosureSEC source: 0001447362-20-000228 · wf-form4_160192830937248.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,423,994 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.940 to $51.920, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 23, 2020 Filed Sep 24, 2020 20:04 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 362 | $52.14 | $18,872.87 |
DisclosureSEC source: 0001447362-20-000225 · wf-form4_160097785726941.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,433,988 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $52.110 to $52.185, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 23, 2020 Filed Sep 24, 2020 20:04 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 2,554 | $51.59 | $131,763.41 |
DisclosureSEC source: 0001447362-20-000225 · wf-form4_160097785726941.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,434,350 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $51.105 to $52.100, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 23, 2020 Filed Sep 24, 2020 20:04 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 3,084 | $50.55 | $155,902.37 |
DisclosureSEC source: 0001447362-20-000225 · wf-form4_160097785726941.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,436,904 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $50.090 to $51.080, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 20:04 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 4,048 | $51.75 | $209,488.05 |
DisclosureSEC source: 0001447362-20-000225 · wf-form4_160097785726941.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,439,988 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $51.610 to $52.120, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 20:04 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 8,552 | $51.32 | $438,845.88 |
DisclosureSEC source: 0001447362-20-000225 · wf-form4_160097785726941.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,444,036 F4 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $50.610 to $51.600, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 20:04 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 9,023 | $51.71 | $466,552.26 |
DisclosureSEC source: 0001447362-20-000225 · wf-form4_160097785726941.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,452,588 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $51.600 to $52.400, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 22, 2020 Filed Sep 24, 2020 20:04 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 14,537 | $51.32 | $745,995.23 |
DisclosureSEC source: 0001447362-20-000225 · wf-form4_160097785726941.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,461,611 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.600 to $51.590, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 20:14 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,710 | $48.64 | $83,181.24 |
DisclosureSEC source: 0001447362-20-000223 · wf-form4_160046002623283.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 833,578 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $48.480 to $48.985, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 20:14 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,040 | $48.30 | $98,525.88 |
DisclosureSEC source: 0001447362-20-000223 · wf-form4_160046002623283.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 835,288 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $47.470 to $48.465, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:14 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,200 | $48.75 | $107,241.20 |
DisclosureSEC source: 0001447362-20-000223 · wf-form4_160046002623283.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 837,328 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $48.285 to $49.240, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:14 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,550 | $47.86 | $74,176.80 |
DisclosureSEC source: 0001447362-20-000223 · wf-form4_160046002623283.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 839,528 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on March 13, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $47.250 to $48.215, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 20:05 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · derivative · entry 7 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,137 Underlying: Common Stock · 13,000 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F6 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 20:05 UTC |
Stokes FrankChief Financial Officer
|
SaleCommon Stock | 7,741 | $49.43 | $382,606.67 |
DisclosureSEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · nonDerivative · entry 5 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,886 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $49.160 to $50.000, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 20:05 UTC |
Stokes FrankChief Financial Officer
|
SaleCommon Stock | 5,259 | $48.52 | $255,145.64 |
DisclosureSEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · nonDerivative · entry 4 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,627 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $48.145 to $49.120, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 20:05 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionCommon Stock | 13,000 | $2.39 | $31,070.00 |
DisclosureSEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · nonDerivative · entry 3 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:05 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · derivative · entry 6 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,137 Underlying: Common Stock · 13,000 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F6 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:05 UTC |
Stokes FrankChief Financial Officer
|
SaleCommon Stock | 13,000 | $49.98 | $649,779.00 |
DisclosureSEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · nonDerivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,886 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.410 to $50.170, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:05 UTC |
Stokes FrankChief Financial Officer
|
Exercise / conversionCommon Stock | 13,000 | $2.39 | $31,070.00 |
DisclosureSEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F2 · balance_after: Includes 826 shares and 1,060 shares acquired on February 28, 2020 and August 31, 2020, respectively, under the Issuer's employee stock purchase plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.